Bico Group Ab Class B · OMXSTO:BICO
Bico Group Ab Class B — Cellink — Investor Presentation (March 2021)
29 slides from Bico Group Ab Class B's investor presentation, Mar 10, 2021
Slide 1: Investor presentation March 10-11, 2021
Investor presentation March 10-11, 2021 Erik Gatenholm, CEO, CELLINK Gusten Danielsson, CFO, CELLINK © CELLINK 2021, All rights reserved.
Slide 2: Bioconvergence
BIOCONVERGENCE © CELLINK 2021, All rights reserved.
Slide 3: The modern healthcare challenges
The modern healthcare challenges High costs and lengthy processes for drugs to A life is lost every hour Animal studies are poor reach patients. 9 out of 10 of the day due to lack of indicators of success for fail in clinical stages! organ transplants human drug development © CELLINK 2021, All right
Slide 4: Bioconvergence is the future of healthcare
Biology + Technology BIOCONVERGENCE IS THE FUTURE OF HEALTHCARE © CELLINK 2021, All rights reserved.
Slide 5: Biotechnology
• Bioconvergence to form the future base of medicine and to reshape the global health industry Technological Bio-Convergence Technological Development Development Software and Engineering Materials Genetic Biotechnology Science Therapy </> Artificial Digitization of Intelligence & Big Biological Dat
Slide 6: The solution is found in bioconvergence
The solution is found in bioconvergence Drug discovery 3D Cell culturing Regenerative CRISPR & gene medicine - tissue editing printing Diagnostics and Single Cell Omics Optics and Biopharmaceuticals biological Imaging sensors 6
Slide 7: Our unique bioconvergence offering
Our unique bioconvergence offering Extrusion based Live-cell imaging bioprinting Assays Omics BIOPRINTING BIOSCIENCES Sample Prep. INDUSTRIAL Light based bioprinting Single cell SOLUTIONS printing & sorting Diagnostics Laser based bioprinting NGS Library Multiplex Prep. Bioreactors OEM manufacturing
Slide 8: Large market opportunities for CELLINK
Large market opportunities for CELLINK Market size Market size The 3D bioprinting market is expected to The CLD market is expected to reach Market size reach $4.4Bn by 2028, +15.8% p.a. and the $6.4Bn by 2025,+10.8% p.a. The single cell The PoC (Point of Care) diagnostics and 3D cell culture market
Slide 9: The bioconvergence market
The bioconvergence market Bioconvergence market opportunity $200Bn+ Bioprocessing The upstream bioprocessing market size is expected to reach $45Bn+ $12.6Bn by 2026, at a CAGR of 12.9% during the period. Cell culture The cell culture market is expected to reach $33.1Bn by 2025, at a CAGR of 11.8% du
Slide 10: Serving our customers in the best possible way in the era of workflows
Serving our customers in the best possible way in the era of workflows Single cell handling robots Bioprinters & Bioinks Liquid handling robots Live cell imaging Drug screening workflow Dispensing single cells to Bioprint tissue using Dispense drug molecules Monitor the treated tissue ensure specifi
Slide 11: Financial summary
FINANCIAL SUMMARY © CELLINK 2021, All rights reserved.
Slide 12: Continued strong organic growth, positive result and strategic investments for the future
Continued strong organic growth, positive result and strategic investments for the future September 2019 – December 2020 Q5: September – December 2020 Net sales amounted to SEK 416,009 thousand (SEK 155,646 Net sales amounted to SEK 239,216 thousand (SEK 50,189 thousand), which corresponds to an
Slide 13: Strong organic growth and important strategic acquisition under continued challenging conditions
Strong organic growth and important strategic acquisition under continued challenging conditions kSEK Sep-Dec 2020 Sep-Dec 2019 Sep 2019-Dec 2020 Sep 2018-Dec 2019 Net sales* 239,216 50,189 416,009 155,646 Net sales Laboratory Solutions* 87,040 - 263,833 - Net sales Industrial Solutions* 152,176 - -
Slide 14: Strong organic growth in combination with improved sales levels in Q5, 2020
Strong organic growth in combination with improved sales levels in Q5, 2020… MSEK NET SALES (LTM) 400 73% Organic Growth Quarter 350 300 250 200 150 100 50 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q5 FY2018/19 FY2019/20 © CELLINK 2021, All rights reserved.
Slide 15: … and continuous resilient gross margins
… and continuous resilient gross margins MSEK 300 GROSS PROFIT & MARGIN (LTM) 85% 250 80% 200 75% 150 70% 100 65% 50 0 60% Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q5 FY2018/19 FY2019/20 © CELLINK 2021, All rights reserved.
Slide 16: Stable revenue from consumables
Stable revenue from consumables MSEK 40 16,0% 35 14,0% 30 12,0% 25 10,0% 20 8,0% 15 6,0% 10 4,0% 5 2,0% 0 0,0% Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q5 Consumables, LTM Proportion of product revenues from consumables, LTM FY2018/19 FY2019/20 © CELLINK 2021, All rights reserved.
Slide 17: Growth per region Q5, 2020 vs Q5, 2019
Growth per region Q5, 2020 vs Q5, 2019 (share of sales, Q5 2020) NORTH EUROPE ASIA AMERICA 30% 49% (31%) (17%) 143% (49%) OTHER -16% (3%) © CELLINK 2021, All rights reserved.
Slide 18: Long-term financial targets 2019-2022
Long-term financial targets 2019-2022 CELLINK’s objective is to achieve an annual organic sales Organic growth growth of >35%, supplemented by strategic acquisitions. EBITDA margin CELLINK’s objective is to have a positive EBITDA margin. CELLINK aims to maintain a ratio of Net Debt to EBITDA Capital
Slide 19: M&A Agenda
M&A AGENDA © CELLINK 2021, All rights reserved.
Slide 20: Customer centric M&A agenda
Customer centric M&A agenda CELLINK invests in entrepreneurs’ enthusiasm and passion for what they do. We aim to find and acquire companies that are built on determined people with a strong desire to create the future of medicine. Financial targets Strategic targets • Revenue growth in line with CEL
Slide 21: Successful integration of acquired companies
Successful integration of acquired companies • €5 MM in transaction value – • ~€30 MM in transaction value – • ~€80 MM in transaction value • ~€70 MM in transaction value 60% in shares / 40% in cash 60% in shares / 40% in cash – 50% / 50% in shares/cash – 40% / 60% in shares/cash • Part of the biopr
Slide 22: Acquisition of Ginolis - main synergies
Acquisition of Ginolis - main synergies Enabling the next generation of bioprinting systems The increased demand for microfluidic and lateral flow IVD tests, PoC-tests Synergies with the Group’s existing product offering and future product development Increased capacity to deliver larger automation
Slide 23: MatTek, a global leader in in-vitro technology and alternative drug testing models
MatTek, a global leader in in-vitro technology and alternative drug testing models "The rat gave us an answer, the monkeys gave us another answer, and the human testing gave us a third answer." MatTek customer © CELLINK 2021, All rights reserved.
Slide 24: Through the strategic acquisition of MatTek, the CELLINK Group will achieve the following
Through the strategic acquisition of MatTek, the CELLINK Group will achieve the following: 1 Provide alternative testing models which enables the reduction, and in some cases elimination, of animal testing. These solutions allow researchers to gather better data through more 2 physiologically releva
Slide 25: The transaction in brief
The transaction in brief Enterprise Value on cash- and debt-free basis of $68 million (20% in shares and remaining in cash). MatTek’s revenue reached $16.6 million in 2020, with and EBITDA margin of 21.9 per cent. Pro-forma revenue growth is expected for 2021 and MatTek’s historical growth rate has
Slide 26: Why increase tissue model testing?
Why increase tissue model testing? • Reduces animal testing • Faster drug development processes • Human in-vitro tissues are the best models of actual human tissues • Great potential for personalized medicine © CELLINK 2021, All rights reserved.
Slide 27: Market potential and growth
Market potential and growth In 2020 the global in vitro testing market without using animals as test models is estimated at $9.1Bn and expected to grow at a CAGR of 10.3% during the forecast period to reach $14.9Bn by 2025. © CELLINK 2021, All rights reserved.
Slide 28: Contact info
CONTACT INFO Erik Gatenholm, CEO eg@cellink.com, phone: +1 (650) 515 5566 Gusten Danielsson, CFO gd@cellink.com, phone: +1 (857) 332 2138 Visit Investor Relations section for more information: www.cellink.com/investors Investor Relations service and requests please contact: ir@cellink.com Next inter
Slide 29: Disclaimer
Disclaimer You must read the following before continuing. The following applies to this document and the information provided in this presentation by CELLINK AB (publ) (the “Company”) or any person on behalf of the Company and any other material distributed or statements made in connection with such